Leland Gershell
Stock Analyst at Oppenheimer
(4.50)
# 265
Out of 5,182 analysts
160
Total ratings
47.68%
Success rate
31.94%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Maintains: Outperform | $10 → $18 | $9.26 | +94.38% | 2 | Apr 21, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $1,060 → $1,014 | $775.03 | +30.83% | 8 | Apr 2, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $110 → $80 | $52.76 | +51.63% | 10 | Mar 18, 2026 | |
| ENGN enGene Therapeutics | Maintains: Outperform | $33 → $30 | $6.96 | +331.03% | 4 | Mar 11, 2026 | |
| OCGN Ocugen | Initiates: Outperform | $10 | $1.66 | +502.41% | 1 | Mar 11, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $125 → $145 | $83.67 | +73.30% | 3 | Mar 9, 2026 | |
| CALC CalciMedica | Maintains: Outperform | $20 → $10 | $0.58 | +1,634.61% | 6 | Mar 5, 2026 | |
| AARD Aardvark Therapeutics | Maintains: Outperform | $35 → $21 | $5.59 | +275.67% | 2 | Mar 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $98 → $95 | $53.30 | +78.24% | 4 | Feb 24, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $246 → $262 | $222.08 | +17.98% | 13 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $283 | $54.77 | +416.71% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $54 | $33.98 | +58.92% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $24 | $13.84 | +73.41% | 4 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $6.09 | +195.57% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $13.61 | +164.51% | 7 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $73 → $87 | $38.15 | +128.05% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $27.20 | +194.12% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $69.71 | -12.49% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $302.11 | +62.19% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.81 | +244.23% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $84.18 | +30.67% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $24.12 | +28.52% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $1.23 | +8,030.08% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $232.32 | -36.73% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.29 | +2,083.41% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $26.99 | +96.37% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.53 | +239.94% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $2.15 | +232,458.14% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.06 | +394.07% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $29.44 | -1.49% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $12.86 | +172.16% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 | $12.46 | +2,308.67% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.08 | +1,751.85% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.85 | +602.70% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $4.12 | +2,812.62% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.85 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $31.62 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $13.96 | - | 5 | Mar 31, 2020 |
Climb Bio
Apr 21, 2026
Maintains: Outperform
Price Target: $10 → $18
Current: $9.26
Upside: +94.38%
argenx SE
Apr 2, 2026
Maintains: Outperform
Price Target: $1,060 → $1,014
Current: $775.03
Upside: +30.83%
Soleno Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $110 → $80
Current: $52.76
Upside: +51.63%
enGene Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $33 → $30
Current: $6.96
Upside: +331.03%
Ocugen
Mar 11, 2026
Initiates: Outperform
Price Target: $10
Current: $1.66
Upside: +502.41%
Dianthus Therapeutics
Mar 9, 2026
Maintains: Outperform
Price Target: $125 → $145
Current: $83.67
Upside: +73.30%
CalciMedica
Mar 5, 2026
Maintains: Outperform
Price Target: $20 → $10
Current: $0.58
Upside: +1,634.61%
Aardvark Therapeutics
Mar 2, 2026
Maintains: Outperform
Price Target: $35 → $21
Current: $5.59
Upside: +275.67%
BioMarin Pharmaceutical
Feb 24, 2026
Maintains: Outperform
Price Target: $98 → $95
Current: $53.30
Upside: +78.24%
Ascendis Pharma
Feb 12, 2026
Maintains: Outperform
Price Target: $246 → $262
Current: $222.08
Upside: +17.98%
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $54.77
Upside: +416.71%
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $33.98
Upside: +58.92%
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $13.84
Upside: +73.41%
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $6.09
Upside: +195.57%
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $13.61
Upside: +164.51%
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $38.15
Upside: +128.05%
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $27.20
Upside: +194.12%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $69.71
Upside: -12.49%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $302.11
Upside: +62.19%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $5.81
Upside: +244.23%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $84.18
Upside: +30.67%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $24.12
Upside: +28.52%
Mar 24, 2025
Initiates: Outperform
Price Target: $100
Current: $1.23
Upside: +8,030.08%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $232.32
Upside: -36.73%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.29
Upside: +2,083.41%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $26.99
Upside: +96.37%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.53
Upside: +239.94%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $2.15
Upside: +232,458.14%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.06
Upside: +394.07%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $29.44
Upside: -1.49%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $12.86
Upside: +172.16%
Apr 9, 2024
Maintains: Outperform
Price Target: $300
Current: $12.46
Upside: +2,308.67%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.08
Upside: +1,751.85%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.85
Upside: +602.70%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $4.12
Upside: +2,812.62%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.85
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $31.62
Upside: -
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $13.96
Upside: -